Friday, December 15, 2017
 
 
Company News: Page (1) of 1 - 08/11/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
3D Signatures Announces Change to Its Board of Directors

(August 11, 2017)

TORONTO, Aug. 11, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF; FSE:3D0) (the "Company" or "3DS"), announces that Helen Stevenson has resigned as a director of the Company effective immediately.

3DS wishes to thank Ms. Stevenson for her contribution, and wishes her all the best in her future endeavors.

The Company will take steps to fill Ms. Stevenson’s vacated seat as soon as practicable.

About 3DS

3DS (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s website at http://www.3dsignatures.com.

Forward-Looking Information

This news release includes forward-looking statements, such as the Company’s intention to fill vacancies on its board of directors, that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: market demand; technological changes that could impact the Company’s existing products or the Company’s ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company’s financial condition; the Company’s ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements. 

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information, please contact:Jason FlowerdayCEO & [email protected]

Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • ApolloMed And Network Medical Management Announce Completion Of Merger And Listing On The Nasdaq Capital Market
  • Global Wireless Health Market Will Reach USD 427 Billion by 2022: Zion Market Research
  • Protein Expression Market, 2023
  • Global Protein Expression Market 2016-2023: Market is Expected to Grow from $1.4 Billion to $3.0 Billion
  • Dental Unit Market To Witness Enhanced Demand From Hospitals And Clinics, Dental Laboratories And Various Healthcare Sectors Till 2022 | Million Insights

    Cancer
  • Targovax to present at DNB healthcare conference
  • Low-Dose Radiation Can Enhance Natural Barriers to Cancer, according to the Journal of American Physicians and Surgeons
  • Kitov Announces Consensi™ as Brand Name for KIT-302
  • BioSight Announces Phase I/II Results of its Cytarabine Pro-Drug BST-236 for Treatment of Acute Leukemia
  • Gastrointestinal Stromal Tumor Market Will be Worth US$ 1.5 Billion by 2026 - Persistence Market Research
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines